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https://doi.org/10.1016/j.stemcr.2018.12.003SUMMARYHeterozygous de novo mutations in GATA6 are the most frequent cause of pancreatic agenesis in humans. In mice, however, a similar
phenotype requires the biallelic loss of Gata6 and its paralog Gata4. To elaborate the human-specific requirements for GATA6, we chose
to model GATA6 loss in vitro by combining both gene-edited and patient-derived pluripotent stem cells (hPSCs) and directed differenti-
ation toward b-like cells.We find thatGATA6heterozygous hPSCs show amodest reduction in definitive endoderm (DE) formation, while
GATA6-null hPSCs fail to enter theDE lineage. Consistentwith these results, genome-wide studies show thatGATA6 binds and cooperates
with EOMES/SMAD2/3 to regulate the expression of cardinal endoderm genes. The early deficit in DE is accompanied by a significant
reduction in PDX1+ pancreatic progenitors and C-PEPTIDE+ b-like cells. Taken together, our data position GATA6 as a gatekeeper to early
human, but not murine, pancreatic ontogeny.INTRODUCTION
Pancreatic agenesis is an extremely rare human condition
resulting from the impaired formation of the pancreas
during embryonic development. Clinically, patients can
entirely lack the pancreas or present with only a partially
formed organ (hypoplasia). The majority of patients have
complete absence of a functioning pancreas, resulting in
intrauterine growth retardation, neonatal diabetes, and
exocrine pancreatic failure, and thus require insulin and
exocrine enzyme replacement therapy. Less commonly,
less severely affected patients can display a reduction in to-
tal islet number or insulin-secreting b cells and present dia-
betic symptoms during adolescence or adulthood.
The vast majority of human pancreatic agenesis cases
owe their genetic origins to mutations in a small handful
of pancreatic regulatory genes. The first described is Pancre-
atic and Duodenal Homeobox 1 (Pdx1) (Schwitzgebel, 2014;
Stoffers et al., 1997). In mice, Pdx1 transcripts label the
incipient pancreatic primordium—two epithelial buds
that are situated dorsally and ventrally on opposite sides
of the posterior foregut around embryonic day 9.5 (Jørgen-
sen et al., 2007; Pan and Wright, 2011). In Pdx1-null
mutant mice, these buds initially form but quickly regress,
resulting in complete pancreatic agenesis, severe hypergly-
cemia, and death within a few days of birth (Ahlgren et al.,Stem C
This is an open access arti1996; Jonsson et al., 1994; Offield et al., 1996). PDX1 simi-
larly labels the human embryonic dorsal and ventral fore-
gut around Carnegie stage 12 (29–31 days post conception)
(Jennings et al., 2013). Significantly, the pathology of hu-
man patients with homozygous or compound heterozy-
gous mutations in PDX1 mirrors the agenesis phenotype
observed in Pdx1-deficient mice (Schwitzgebel et al.,
2003; Stoffers et al., 1997).
The most common cause of pancreatic agenesis in hu-
mans is heterozygous mutations in the GATA6 gene (De
Franco et al., 2013; Lango Allen et al., 2011).GATA6 encodes
a highly conserved zinc-finger transcription factor that rec-
ognizes and binds the (A/T)GATA(A/G) regulatory motif,
two of which are located in the mouse Pdx1 and human
PDX1 promoters (Carrasco et al., 2012; Lentjes et al., 2016;
Patient and McGhee, 2002; Viger et al., 2008; Xuan et al.,
2012). GATA6, along with its five other family members
(GATA1–5), functions in diverse cellular contexts, from
coordinating morphogenesis during embryonic develop-
ment to themaintenanceof lineage-specific gene expression
in adult hematopoietic stem cells (Lentjes et al., 2016; Viger
et al., 2008). Gata6 is expressed in the definitive endoderm
(DE) that emerges during gastrulation, as well as its deriva-
tive the gut tube epithelium and the early pancreas primor-
dium (Freyer et al., 2015; Morrisey et al., 1996). Gata6
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morphogenesis, becoming restricted in later development
to the ductal epithelial compartment and a subset of endo-
crine cells (Decker et al., 2006; Ketola et al., 2004).
In contrast to PDX1, GATA6 mutations that result in
pancreatic agenesis are heterozygous and predominantly
de novo (Chao et al., 2015; De Franco et al., 2013; Lango Al-
len et al., 2011; Stanescu et al., 2015; Suzuki et al., 2014).
The majority of cases have full pancreatic agenesis, but
there are some associated with incomplete penetrance, re-
sulting in a broad spectrum of clinical manifestations (De
Franco et al., 2013). At the extreme, family members with
the same inheritedGATA6 allele can present withmarkedly
different phenotypes (Bonnefond et al., 2012; Yau et al.,
2017; Yorifuji et al., 2012). In addition, GATA6 patients
usually display a number of extrapancreatic abnormalities,
including congenital heart defects, as well as several whose
origins are endodermal—hepatobiliarymalformations, gall
bladder agenesis, and gut herniation (Chao et al., 2015; De
Franco et al., 2013; Lango Allen et al., 2011).
Given the observations that haploinsufficiency results in
severe pancreatic and non-pancreatic anomalies in hu-
mans, it is surprising that Gata6 heterozygous null mice
are viable and fertile, with no reported abnormalities (Kout-
sourakis et al., 1999; Morrisey et al., 1998). In a recent
study, Schrode et al. (2014) showed that the specification
of the extraembryonic primitive endoderm entirely fails
in Gata6 homozygous embryos at the blastocyst stage,
while in a series of older reports Gata6-null mutant em-
bryos were recovered at post-implantation stages with de-
fects in the cardiac mesoderm and visceral endoderm
(Koutsourakis et al., 1999; Morrisey et al., 1998). Interest-
ingly, tetraploid complementation experiments between
wild-type embryos and Gata6-deficient embryonic stem
cells, a technique that overcomes the early lethality result-
ing from the absence of Gata6 in the extraembryonic line-
ages, reveal thatGata6-deficient cells can indeed contribute
descendants to the DE in chimeric embryos (Zhao et al.,
2005). Moreover, conditional loss of Gata6 specifically in
Pdx1+ pancreatic progenitors has no impact on pancreatic
morphogenesis. Only when a closely related gene,Gata4, is
simultaneously deleted is an agenesis phenotype recovered
that resembles GATA6 heterozygous human patients (Car-
rasco et al., 2012; Xuan et al., 2012).
The striking discrepancy between the mouse and the hu-
man phenotypes and the complex genetic landscape of
GATA6 agenesis patients led us to model GATA6 deficiency
in vitro using human pluripotent stem cells (hPSCs). We
generated a large panel of heterozygous, homozygous,
and compound heterozygous GATA6 mutations by per-
forming genome editing in human embryonic stem
cells (hESCs) and human induced pluripotent stem cells
(hiPSCs). We additionally derived hiPSCs from two
GATA6 heterozygous pancreatic agenesis patients. Subject-58 Stem Cell Reports j Vol. 12 j 57–70 j January 8, 2019ing theseGATA6 heterozygous hPSCs to directed differenti-
ation into the pancreatic lineage unexpectedly revealed a
modest requirement for wild-type GATA6 gene dosage for
robust formation of the DE. In contrast to the mouse, com-
plete loss of GATA6 abrogates DE production. Consistent
with these results, genome-wide studies show that GATA6
binds and cooperates with EOMES/SMAD2/3 to regulate
the expression of cardinal endoderm genes. In addition,
GATA6 haploinsufficiency diminishes the ability of those
DE cells that form to become PDX1+ pancreatic progenitors
and to further mature into C-PEPTIDE-containing b-like
cells. These findings show that in humans, the formation
of DE and acquisition of pancreatic fate are exquisitely sen-
sitive to GATA6 gene dosage.RESULTS
GATA6 Expression during Directed Differentiation of
hPSCs into the Endocrine Lineage
Consistent with Gata6 expression in the mouse embryo,
we previously showed that GATA6 is activated during the
early differentiation of hESCs into the DE lineage (Teo
et al., 2015; Vallier et al., 2009). We next determined the
precise expression kinetics of GATA6 during extended dif-
ferentiation into the pancreatic lineage using the well-
characterized hESC line H9 and a slightly revised version
of an 18-day chemically defined protocol previously pub-
lished by our group (Figure S1A and see Experimental Pro-
cedures for complete details) (Cho et al., 2012). GATA6
transcripts are not detected in undifferentiated hESCs,
but are abundant by day 3, a time point characterized by
the expression of canonical DE markers (SOX17, GATA4,
FOXA2, and HNF4A) (Figure S1B). Roughly, 75% and
98% of cells on day 3 are SOX17+ and GATA6+, respec-
tively (Figure S1D). GATA6 expression persists from day 6
onward, coinciding with the activation of the signature
pancreatic lineage marker PDX1 (Figure S1B). By day 12,
GATA6 is co-expressed with genes associated with endo-
crine commitment (NGN3 and NKX6-1), with approxi-
mately 76% and 88% of the differentiated cells PDX1+ or
GATA6+, respectively (Figures S1B and S1E). The expression
of islet hormone genes (INSULIN, GLUCAGON, and
SOMATOSTATIN) increases from day 12 (Figure S1B).
Importantly, immunofluorescence (IF) staining reveals co-
localization of SOX17 and GATA6 in day 3 DE as well as
PDX1 and GATA6 in day 12 pancreatic endoderm (PE)
(Figure S1C). These data were confirmed in a healthy hiPSC
line, FSPS13.B, hereafter designated 13.B (Figures S2A–
S2C). Taken together, these findings establish develop-
mental windows where GATA6 insufficiency can result in
the pancreatic hypoplasia observed in human GATA6 het-
erozygous patients.
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Figure 1. Derivation and Characterization of GATA6 Mutant Lines
(A) Schematic of the GATA6 locus. Gray shading highlights the 50 and 30 untranslated regions. The TALEN cut site lies downstream of the
second start ATG in exon 2. Successful gene editing in H9 cells yielded a GATA6 heterozygous line containing a 4-bp insertion (GATA64ins/+)
(legend continued on next page)
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Generation of GATA6Mutant Alleles Using TALENs
and Derivation of hiPSCs from Two Independent
GATA6 Heterozygous Patients
To pinpoint the precise role of GATA6 in the human
pancreatic lineage, we performed genome-editing in
hPSCs as well as isolated patient-derived hiPSCs to
generate a panel of GATA6 mutant alleles to model
pancreatic agenesis in vitro. The human GATA6 gene is
transcribed from two distinct promoter regions, contains
two initiation codons in exon 2 (a second at Met147),
and consequently encodes two GATA6 protein isoforms,
with masses of 60 and 45 kDa, respectively (Figure 1A;
Brewer et al., 1999). We initially targeted both H9 and
13.B at a TALEN cut site immediately 30 of the first ATG
in GATA6. Despite the introduction of frameshift muta-
tions that result in premature stop codons, translation
still initiated at the second ATG, producing the shorter
GATA6 isoform at wild-type levels (data not shown).
Thus, in subsequent experiments, we targeted GATA6
at a second TALEN cut site 30 of the second ATG
(Figure 1A) and successfully recovered GATA6 heterozy-
gous (GATA6c.618_619insTGCA/+, hereafter GATA64ins/+)
and homozygous (GATA6c.611_614delACCT/c.611_614delACCT,
hereafter GATA6D4/D4) mutations in H9 cells. We
generated similar insertion or deletion alleles, both
heterozygous (GATA6c.del614_627TGCAGGGGTCGGGC/+, here-
after GATA6D14/+) and compound heterozygous
(GATA6c.del614_627TGCAGGGGTCGGGC/c.del613_623CTGCAGGGGTC,
hereafter GATA6
D14/D11
), in 13.B. In parallel, we inserted
an emerald GFP (emGFP) reporter in-frame with the
first GATA6 ATG via homologous recombination
(GATA6GFP/+) in H9 cells (Figures 1C and 1D) and 13.B
cells. An H9 GATA6GFP homozygous clone was also recov-and a homozygous line with an identical 4-bp deletion on each chrom
coding sequence (green) and a premature stop. H9* cells were subjec
(B) OCT4, SOX2, and NANOG immunofluorescence in H9*, GATA64ins/+,
Scale bars, 100 mm.
(C) A second TALEN cut site downstream of the first ATG in exon 2 of
introduces an emerald GFP (emGFP) reporter in-frame and a puromycin
in both heterozygous (GATA6GFP/+) and homozygous (GATA6GFP/GFP) m
(D) Immunofluorescence showing emGFP-expressing heterozygous G
differentiation. Scale bars, 100 mm.
(E) PCR showing loss of transgenes in a patient A mutant hiPSC line, c
three independent clones derived from either patient A or patient B.
(F and G) Genotype confirmation by Sanger sequencing of two GATA6
patient B, GATA6c.1136–2A>G/+.
(H) Immunofluorescence confirming the successful reprogramming an
Scale bars, 200 mm. Images are representative of three independent cl
(I) Western blot analysis of GATA6 and GATA4 protein levels in
GATA6GFP/GFP mutant cells, as well as the two patient-derived mutan
a-tubulin was used as a loading control. Long and short isoforms of w
products for GATA64ins/+ are 30 and 18 kDa for the long and short isof
27 and 15 kDa for the long and short isoforms, respectively. No GATA
60 Stem Cell Reports j Vol. 12 j 57–70 j January 8, 2019ered (GATA6GFP/GFP) (Figure 1C). Unfortunately, no 13.B
GATA6GFP homozygous clone was recovered despite
numerous attempts. Control TALEN-targeted lines that
harbor no mutations in GATA6 (designated H9* or
13.B*) served as wild-type, isogenic positive controls for
differentiation experiments involving genome-edited
hPSCs. Last, we obtained fibroblasts from two GATA6 het-
erozygous patients, whose mutations were previously
described (De Franco et al., 2013; Yu et al., 2014). Patient
A contains a missense mutation (c.1366C>T) at a highly
conserved amino acid within the second zinc-finger
DNA-binding domain (Arg456Cys) (Figure 1F), while pa-
tient B contains a splice acceptor mutation in exon 3
(GATA6c.1136–2A>G/+) (Figure 1G). Three independent
hiPSC clones were isolated for each patient line. All
hESC and hiPSC lines were found to have a normal karyo-
type by multiplex fluorescence in situ hybridization (see
Supplemental Experimental Procedures) and assayed by
immunohistochemistry to confirm their pluripotency
(Figures 1B and 1H and data not shown). hiPSC lines
were also monitored for absence of the Sendai virus
(Figure 1E).
Differentiation of GATA6Mutant hPSC Lines into the
Definitive Endoderm Lineage
Mutant lines were next differentiated to the DE stage and
GATA6 protein levels determined by western blot using
anti-N- and anti-C-terminal GATA6 antibodies (Figure 1I).
In H9* DE cells, both GATA6 isoforms are detected by the
N-terminal antibody, whereas the C-terminal antibody pre-
dominantly recognizes the short isoform (Figure 1I)
(Brewer et al., 1999). GATA64ins/+ and GATA6D4/D4 contain
frameshift mutations that result in truncated partialosome (GATA6D4/D4). Each mutation results in the addition of novel
ted to gene editing and selection, but have no mutation in GATA6.
and GATA6D4/D4 lines confirms pluripotency in gene-edited clones.
GATA6 is depicted. Cartoon schematic of the ‘‘knockin’’ vector that
-resistance cassette. Successful homologous recombination resulted
utant cells
ATA6GFP/+ and homozygous GATA6GFP/GFP mutant cells on day 3 of
lone 1, compared with positive controls. Data are representative of
patient-derived hiPSC lines: (F) patient A, GATA6R465C/+, and (G)
d pluripotency of one patient A-derived (GATA6R465C/+) mutant line.
ones derived from either patient A or patient B (GATA6c.1136–2A>G/+).
undifferentiated H9*, GATA64ins/+, GATA6D4/D4, GATA6GFP/+, and
t lines: patient A, GATA6R465C/+, and patient B, GATA6c.1136–2A>G/+.
ild-type GATA6 are 60 and 45 kDa, respectively; the partial protein
orms, respectively; the partial protein products for GATA6D4/D4 are
6 protein was present for the GATA6GFP/GFP mutant.
Figure 2. GATA64ins/+ and GATA6D4/D4 Mutant hESC Lines Display Impaired DE Formation
(A) Expression of pluripotency (OCT4, SOX2), primitive streak (BRACHYURY), mesendoderm (EOMES), and definitive endoderm (CXCR4,
SOX17, GATA4) markers, as well as GATA6 itself, in H9* and H9-derived GATA64ins/+ and GATA6D4/D4 mutant cells over 3 days of differ-
entiation (Figure S1A).
(B) Differentiation efficiency measured by FACS analysis of CXCR4 and SOX17 at day 3 DE in H9* and H9-derived GATA64ins/+ and GATA6D4/D4
mutant cells.
(C) Immunofluorescence analyses for the key DE markers GATA6 with SOX17 in H9* and H9-derived GATA64ins/+ and GATA6D4/D4 mutant
cells. DAPI, 40,6-diamidino-2-phenylindole. Scale bars, 100 mm.
(legend continued on next page)
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protein products predicted to contain 205 and 203 N-ter-
minal amino acids, respectively, of the longer GATA6
isoform as well as additional novel C-terminal sequences
(Figures 1A and 1I) that terminate before the two C-termi-
nal zinc-finger DNA-binding domains. The insertion of the
GFP reporter and puromycin-resistance cassettes in GATA6
exon 2 generates a loss-of-function allele, since neither
wild-type GATA6 isoform nor novel partial protein prod-
ucts were observed in GATA6GFP/GFP knockin H9 cells (Fig-
ures 1C and 1I).
Using the H9-derived GATA64ins/+ and GATA6D4/D4 lines,
we next asked whether reduced levels of GATA6 have an
impact on early mesendoderm (corresponding to days 1
and 2) to DE (day 3) differentiation. qRT-PCR analyses
show that in H9*, GATA64ins/+, and GATA6D4/D4 cells, the
levels of the pluripotency markers OCT4 and SOX2 were
comparable in undifferentiated cells and expectedly
declined during differentiation (Figure 2A). The expres-
sion of primitive streak (BRACHYURY) and mesendoderm
(EOMESODERMIN [EOMES]) markers was also relatively
unchanged across the control H9* and GATA6 mutant
lines, suggesting that early mesendoderm formation was
not affected by either single or biallelic loss of GATA6 (Fig-
ure 2A). Key DE markers SOX17 and CXCR4 were, how-
ever, modestly downregulated beginning on day 2 in
GATA64ins/+ cells (Figure 2A), and on day 3, GATA64ins/+
differentiations yielded roughly 25% fewer SOX17+
cells by fluorescence-activated cell sorting (FACS) and
IF compared with wild-type H9* (Figures 2B and 2C).
This heterozygous effect on SOX17 transcription was
also observed to varying degrees in H9-GATA6GFP/+
and 13.B-derived GATA6D14/+ as well as in patients A
(GATA6R456C/+) and B (GATA6c.1136–2A>G/+) (Figures S2D–
S2F). Interestingly, this heterozygous effect was not
observed in 13.B-derived GATA6GFP/+ (Figure S2E).
Further depleting GATA6 with homozygous (GATA6D4/D4
or GATA6GFP/GFP) or compound heterozygous (13.B-
GATA6D14/D11) allelic combinations dramatically affects
DE formation, yielding 3% SOX17+ cells on day 3 (Fig-
ure 2B and data not shown). We further validated these
results using the commercially available STEMdiff pancre-
atic progenitor kit from STEMCELL Technologies. Using
this differentiation platform, H9*, GATA64ins/+, and
GATA6D4/D4 formed DE at efficiencies indistinguishable
from the results obtained with the protocol outlined in(D) Expression of pluripotency (OCT4) and definitive endoderm (SOX17
mutant cells on days 3 and 6 of differentiation with the STEMdiff pan
(E) Differentiation efficiency measured by FACS analysis of CXCR4 and S
mutant cells differentiated using the STEMdiff pancreatic progenitor
(A and D) Error bars represent the SE of three independent experimen
(B and E) Undifferentiated hESCs stained with the respective primary
both used as controls. Gates were set according to an hESC control.
62 Stem Cell Reports j Vol. 12 j 57–70 j January 8, 2019Figure 1A (cf. Figures 2A and 2B with 2D and 2E). Taken
together, these findings show that diminished levels of
GATA6 compromise early DE formation, and complete
loss of GATA6 significantly perturbs the gene regulatory
network (GRN) governing human DE specification.
Establishing the GATA6 Gene Regulatory Network
To establish comprehensively how GATA6 mutations
alter the DE transcriptional network, we performed
RNA sequencing (RNA-seq) for H9*, GATA64ins/+ and
GATA6D4/D4, and patient A cells on day 3 of differentiation.
Comparative analyses revealed 7,472 genes that are differ-
entially expressed (adjusted p% 0.01; fold changeR2) be-
tween H9* and GATA6D4/D4, 2,898 genes between H9* and
GATA64ins/+, and 6,977 genes between H9* and hiPSC
clones 1 to 3 from patient A (Table S1). We observed that,
consistent with our qRT-PCR data in Figure 2, GATA6D4/D4
mutant cells show significantly decreased expression of
cardinal endoderm markers (e.g., SOX17, CXCR4, HNF1B,
and FOXA2) (Figure 3A). Similar results were observed
when wild-type H9* was compared with GATA64ins/+ and
hiPSC clones 1 to 3 from patient A (Figures 3A and S3A).
We also performed GATA6 chromatin immunoprecipita-
tion followed by high-throughput sequencing (ChIP-seq)
on H9* and GATA64ins/+ cells at the DE stage. This analysis
yielded 12,098 peaks (irreproducible discovery rate%0.05;
median peak length = 417 bp) that are associated with
10,669 genes, 4,790 of which are protein coding (Table
S1). Interestingly, we observe that GATA6 binding is en-
riched at the GATA4 locus in H9 cells, suggesting that
GATA6 directly regulates GATA4 during DE specification
(Figure 3B). Both qRT-PCR and RNA-seq show dose-depen-
dent effects of GATA6 on GATA4 expression levels in
GATA64ins/+ and GATA6D4/D4 mutant cells (Figures 2A, 3A,
and 3B).
We next compared our RNA-seq and ChIP-seq datasets to
identify those genes bound and regulated by GATA6. This
analysis revealed 1,120 protein-coding genes that are
bound by GATA6 in wild-type H9* but are downregulated
in GATA6D4/D4 mutant cells, including pancreatic progeni-
tor genes such as HNF1B and HNF4A (Figure 3C). In
contrast, 745 genes are bound by GATA6 in H9* and upre-
gulated inGATA6D4/D4. Similar overlaps were performed for
GATA64ins/+ and patient A day 3 RNA-seq samples, yielding
337 and 607 GATA6-bound and downregulated genes, and, CXCR4) markers in H9* and H9-derived GATA64ins/+ and GATA6D4/D4
creatic progenitor kit.
OX17 at day 3 DE in H9* and H9-derived GATA64ins/+ and GATA6D4/D4
kit.
ts. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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SOX4, SMAD2, BAD, ISL1,
TCF7L2, HHEX, BAK1, ACVR2B,
MEIS2, GATA6, EIF2AK3, BMP5,
BMP6
Up-regulated in GATA6 Δ4/Δ4
Skeletal system
development
2.66E-06 THRA, NDST1, HEXB, EDN1,
TGFB3, BCAN, GJA5, TGFB2,
MBTD1, INSIG2, PAX7, TRIM45,
CHST11, RAB23, PHOSPHO1,
HHIP, ANO6, ALX1, COL10A1
Mesoderm forma on 0.001386 FGFR2, SIX2, SMAD3, ITGA3,
WLS, PAX2, SNAI1, WNT3,
DKK1, HAND1, SFRP2, ITGA8,
EPB41L5, FOXC1, TLX2, ACVR1
Up-regulated
Figure 3. GATA6 Is a Key Regulator of the DE Transcriptional Network
(A) Heatmap illustrating differential gene expression of key germ layer markers via RNA-seq between H9* cells and H9-derived GATA64ins/+
and GATA6D4/D4 mutant cells at the DE stage. n = 3 biological replicates for each cell line.
(legend continued on next page)
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254 and 616 GATA6-bound and upregulated genes, respec-
tively (Figures S3B and S3C). At the intersection of these
comparisons are 143 commonly downregulated and 104
upregulated genes among GATA6D4/D4, GATA64ins/+, and
patient A samples (Figures S3D and S3E). Key endoderm
markers CXCR4, SOX17, GATA4, HNF1B, and HNF4A
were among the 143 genes commonly downregulated
(Figure S3D).
To infer genes that are directly targeted and regulated by
GATA6, we performed binding and expression target anal-
ysis (BETA) to integrate our H9ChIP-seq dataset with differ-
ential gene expression data from GATA6D4/D4, GATA64ins/+
and patient A (Wang et al., 2013). Targets predicted by
BETA were then subjected to gene ontology analyses using
the DAVID tool (Huang da et al., 2009a, 2009b). We found
that endoderm development is consistently upregulated in
H9* compared with GATA6D4/D4 (Figure 3D), GATA64ins/+
(Figure S3F), and patient A (Figure S3G) mutant cells. In
addition, mesoderm development is consistently upregu-
lated in GATA6D4/D4 (Figure 3D), GATA64ins/+ (Figure S3F),
and patient A (Figure S3G) mutant cells compared with
H9*. Motif analyses generated by BETA confirm that the
GATA recognition motif is highly enriched in both ‘‘up’’
and ‘‘down’’ target genes (Figure S3H). We were unable to
conclude from the BETA whether GATA6 has activating
or repressive functions, or both, as the data were not signif-
icant. Thus, we propose that the most parsimonious
explanation for the upregulation of mesodermal markers
is aberrant differentiation. In the absence of GATA6, differ-
entiation into the DE lineage is blocked, but differentiating
cells remain bathed in high levels of two potent mesoderm
inducers (Activin and BMP4) (Cho et al., 2012). Taken
together, these results show that GATA6 is indispensable
in driving the development of the human DE.
We previously established that the T-box transcription
factor EOMES interacts with the Activin/Nodal effector
proteins SMAD2/3 to deploy the GRN that directs DE
formation. We thus sought to establish how GATA6 inte-
grates into the SMAD2/3/EOMES signaling network by
comparing our GATA6 day 3 ChIP-seq data with previously
published SMAD2/3 and EOMES ChIP-seq (Brown et al.,
2011; Teo et al., 2011). Remapping of the data resulted in(B) ChIP-seq binding profiles of H9* and GATA64ins/+ showing GATA6 en
H9-derived GATA64ins/+ and GATA6D4/D4 mutant cells at the DE stage. Th
ChIP-seq binding profile is derived from merging two biological repli
(C) Venn diagram indicating the overlap of GATA6-bound genes from C
H9-derived GATA6D4/D4 mutant cells compared with H9* cells by R
the table.
(D) Enriched gene ontology showing developmental pathways from
H9-derived GATA6D4/D4 mutant cells derived from BETA analysis.
(E) Density heatmaps of GATA6-binding peak intensity at DE indica
SMAD2/3 and EOMES, within a 5-kb window centered at the transcrip
64 Stem Cell Reports j Vol. 12 j 57–70 j January 8, 201916,303, 20,089, and 2,613 peaks for GATA6, EOMES, and
SMAD2/3, respectively. Of the 16,303 GATA6 ChIP-seq
peaks, 950/2,613 (36.4%) overlap with SMAD2/3, and
8,126/20,089 (40.5%) overlap with EOMES in DE cells,
with 858 common to all three datasets (Figure 3E, Table
S1). In the EOMES/GATA6/SMAD2/3 intersection, we find
almost all of the telltale endodermal regulator genes,
including SOX17, EOMES, LHX1, MIXL1, FOXA2, HNF1B,
and CXCR4. These data therefore place GATA6 centrally
within the core nuclear transcriptional machinery that
governs the acquisition of DE fate.
GATA6 Deficiency Impairs Pancreatic Lineage
Commitment
We further analyzed the effects of GATA6 heterozygous
mutations on pancreatic lineage commitment at the PE
(day 12) and endocrine progenitor (EP) (day 24) stages (Fig-
ure S1A). Key pancreatic markers such as HNF4A, HLXB9,
PDX1, and INSULIN are significantly downregulated in
GATA64ins/+ and GATA6GFP/+ mutant cells at both stages,
with one exception: HLXB9 levels in GATA6GFP/+ are no
different from those in H9* on day 24 (Figure 4A).
HNF4A, PDX1, and INSULIN were also significantly
decreased in 13.B-GATA6D14/+ and 13.B-GATA6GFP/+ and
in patient A and B mutant cells on days 12 and 24 (Figures
S4A and S4B). FACS analysis for PDX1 on day 12 reveals an
approximately 50% decrease in the number of PDX1-posi-
tiveGATA64ins/+ andGATA6GFP/+ cells and 13.B-GATA6GFP/+
cells (Figures 4B and S4C). 13.B-GATA6D14/+, patient A, and
patient B cell lines exhibit an approximately 80%–90%
decrease in PDX1 (Figures S4C and S4D). At the EP stage,
all GATA6 heterozygous mutant cell lines share a common
phenotype, with a strong decrease in the number of
C-PEPTIDE+ cells (Figure 4C, S4C, and S4D). Immunostain-
ing on H9* and GATA64ins/+ cells confirms the dimin-
ished number of SOMATOSTATIN-, C-PEPTIDE-, and
GLUCAGON-positive cells in GATA64ins/+ cells (Figure 4D).
We also performed RNA-seq at the PE stage (day 12) for
H9*, GATA64ins/+, and patient A cells. H9* RNA-seq largely
reproduced a previous dataset generated using both H9
and the same differentiation protocol (Spearman’s rank
correlation coefficient, r = 0.77 for in vitro multipotentrichment near GATA4, and GATA4 expression by RNA-seq in H9* and
e input control profile (IgG control) is included for comparison. The
cates.
hIP-seq at the DE stage with downregulated or upregulated genes in
NA-seq. Key bound genes up- or downregulated are indicated in
direct target genes differentially expressed between H9* and
ting direct overlap with known endodermal regulators, including
tion start site.
Figure 4. Decreased Levels of GATA6 at the DE Stage Influence Downstream Pancreatic Differentiation
(A) Expression of DE (SOX17, GATA6, GATA4, and FOXA2), pancreatic (HNF4A, HLXB9, and PDX1), and endocrine (INSULIN) marker genes in
H9* and H9-derived GATA64ins/+ and GATA6D4/D4 mutant cells at the four key stages of the 24-day pancreatic differentiation protocol
(Figure S1A).
(B) Percentage of PDX1-positive cells in H9-derived GATA64ins/+ and GATA6GFP/+ lines on day 12 shown relative to H9* (100%) as measured
by FACS.
(C) Percentage of C-PEPTIDE-positive cells in H9* and H9-derived GATA64ins/+ and GATA6GFP/+ mutant lines at the EP stage (day 24) as
measured by FACS.
(legend continued on next page)
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pancreatic progenitor cells [MPCs] and r = 0.59 for in vivo
MPCs isolated fromCarnegie stage 16–18 human embryos,
p < 2.2 3 1016) (Cebola et al., 2015). Between H9* and
GATA64ins/+ (Table S1), 1,423 genes were differentially ex-
pressed, and between H9* and patient A, 6,093 were differ-
entially expressed (Table S1). We observed that, consistent
with qRT-PCR and FACS results, GATA64ins/+ and patient A
gene expression quantified by RNA-seq in mutant cells dis-
plays a decreased pancreatic signature (Figures 4E and S4E).
Finally, the above results were independently confirmed
with H9*, GATA64ins/+, and GATA6D4/D4 cells using the
STEMdiff pancreatic progenitor kit: GATA64ins/+ cells
show decreased PDX1 and NKX6-1 expression beginning
on day 9, yielding 50% fewer PDX1+ pancreatic progeni-
tors on day 12 (Figures 4F and 4G). Collectively, these
in vitro findings strongly argue that decreased levels of
GATA6 first influence the formation of DE, and predict
that with fewer DE cells at the time of allocation to the
pancreatic lineage in vivo, hypoplasia emerges.DISCUSSION
Deriving iPSC lines and the ability to rapidly engineer mu-
tations in hPSCs have made human disease modeling
in vitro commonplace. In the case of the well-characterized
set of genes known to control mammalian pancreatic
development, it is the expectation based on strong evolu-
tionary conservation that phenotypes observed in
knockout mouse models will be reproduced in human
and in vitro. Indeed, the matching of human and mouse
pancreatic and extrapancreatic phenotypes is seen for
many recessive loss-of-function mutations in key pancre-
atic developmental transcription factors, e.g., PDX1,
PTF1A, RFX6, NEUROD1, NGN3, and NKX2-2 (Ahlgren
et al., 1996; Flanagan et al., 2014; Jonsson et al., 1994; Off-
ield et al., 1996; Rubio-Cabezas et al., 2010, 2011; Schwitz-
gebel et al., 2003; Sellick et al., 2004; Smith et al., 2010;
Stoffers et al., 1997). Such consistency in phenotype is,
however, not observedwithGata6. Inmice, only the simul-
taneous inactivation of Gata6 and Gata4 results in pancre-
atic agenesis (Carrasco et al., 2012; Xuan et al., 2012),
whereas in humans de novo heterozygous mutations in(D) Immunofluorescence analyses for the key PE markers SOMATOST
H9-derived GATA64ins/+ cells at the EP stage (day 24). DAPI, 40,6-diam
(E) Heatmap illustrating differential gene expression of key pancreati
GATA64ins/+ mutant cells at the PE stage. n = 3 biological replicates f
(F) Expression of DE (GATA6 and GATA4) and pancreatic (HNF4A, PDX1
GATA6D4/D4 mutant cells at key stages of the differentiation protoco
(G) Percentage of PDX1-positive cells in GATA64ins/+ and GATA6GFP/+ lin
cells differentiated using the STEMdiff pancreatic progenitor kit.
(A–C, F, and G) Error bars represent the SE of three independent expe
66 Stem Cell Reports j Vol. 12 j 57–70 j January 8, 2019GATA6 underlie a similar pathology (De Franco et al.,
2013; Lango Allen et al., 2011). However, GATA6 heterozy-
gous phenotypes range from total pancreatic agenesis to
isolated diabetes in young adulthood. This phenotypic
diversity partly explains the difficulties in precisely
modeling GATA6 haploinsufficiency in vitro across labora-
tories and across differentiation platforms, as evidenced
by comparing our present findings with two recent reports
from Shi et al. (2017) and Tiyaboonchai et al. (2017).
Here, we find a modest reduction (25%) in the produc-
tion of DE after 3 days of directed differentiation irrespec-
tive of whether the GATA6 heterozygous line was patient
derived or generated by gene editing in hPSCs. These find-
ings are consistent with GATA6 expression in the DE, but
contrast with the results of Shi et al. (2017) and Tiyaboon-
chai et al. (2017). These authors did not observe decreased
DE formation using assorted GATA6 heterozygous hPSC
lines.Onepotential explanation for these discrepant results
is that GATA6 partial protein products, generated, for
example, from the GATA64ins/+ allele in H9 cells, act in our
hands in a dominant negativemanner, further suppressing
GATA6 levels and compromisingnormalDE formation (Fig-
ure 1I). The partial protein products encoded by the
GATA64ins/+ locus are predicted to retain a long stretch of
the N-terminal GATA6 transactivation domain but lack
the zinc-finger DNA-binding domain and nuclear localiza-
tion signal. As they are able neither to bindDNAnor to het-
erodimerizewithGATA4 (Charron et al., 1999;Maeda et al.,
2005), the biochemical mechanism by which such partial
protein products interfere with GATA6 transcription or
function is entirely unclear. Moreover, Tiyaboonchai et al.
(2017) and Shi et al. (2017) also observe partial protein
products in their GATA6 heterozygous hPSC lines, but do
not observe effects during DE differentiation. Themost sig-
nificant evidence against dominant interference and in
favor of a simple dosage effect comes from the fact that pa-
tientAandB iPSCs,whosemutations donot result inpartial
protein products (Figure 1I), also showdecreasedDE forma-
tion on day 3. Alternatively, because each group employed
different hESC and iPSC lines, the specter of well-known
line-to-line variations in differentiation efficiency could
explain the results from the different laboratories (Cahan
and Daley, 2013; Ortmann and Vallier, 2017).ATIN (SST), C-PEPTIDE (C-PEP), and GLUCAGON (GCG) in H9* and
idino-2-phenylindole dihydrochloride. Scale bars, 100 mm.
c progenitor markers via RNA-seq between H9*cells and H9-derived
or each cell line.
, and NKX6-1) marker genes in H9* and H9-derived GATA64ins/+ and
l using the STEMdiff pancreatic progenitor kit.
es on day 12 shown relative to H9* (100%) as measured by FACS in
riments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Despite these differences among the GATA6 heterozy-
gous phenotypes at the DE stage, complete loss of GATA6
was found by Tiyaboonchai et al. (2017), Shi et al. (2017),
and us (Figure 2), as well as more recently by Liao et al.
(2018) with short hairpin RNA targetingGATA6 in H1 cells,
to unequivocally impair DE formation, a result high-
lighting not only the requirement for wild-type GATA6
gene dosage for robust DE specification in humans but
also the dramatic species-specific differences between
mice and humans. Importantly, our genome-wide studies
place GATA6 among the core transcriptional machinery
that controls DE formation. We previously reported that
the pluripotency factors OCT4, SOX2, and NANOG bind
cooperatively and control the expression of the T-box tran-
scription factor gene EOMES (Teo et al., 2011). Upon activa-
tion, EOMES, jointly with SMAD2/3, the intracellular
effectors of ACTIVIN/NODAL signaling, deploys a large
part of the transcriptional network governing DE forma-
tion. Here, we find 858 genes that are bound within 5 kb
of the transcription start site by EOMES, SMAD2/3, and
GATA6. Importantly, such cooperation has not been
evidenced in mouse development, suggesting major diver-
gences between species in the molecular mechanisms
controlling germ-layer specification. Considering the
importance of GATA6 in specification of extraembryonic
endoderm, this divergence in signaling pathways could
result in the rewiring of downstream transcriptional net-
works with major consequences on the subsequent specifi-
cation of DE.
With extended differentiation to the PE stage (day 12),
we observe significantly decreased numbers of PDX1+
cells—between 50% and 90% fewer compared with wild-
type depending on the GATA6 heterozygous line. This
result is consistent with GATA6 expression in human
pancreatic progenitors (Figure S1C) and with GATA6
directly regulating PDX1 transcription (Carrasco et al.,
2012; Xuan et al., 2012) and also suggests that GATA6 plays
a dual role in both early DE formation and allocation to the
pancreatic lineage. The diminished numbers ofGATA6 het-
erozygous PDX1+ progenitors that emerge at the PE stage
ultimately differentiate into %10% C-PEPTIDE+ cells by
the EP stage (day 24), across all cell types and across all
alleles.
It is tempting to consider that the variation in clinical
phenotype and the early phenotype in DE formation
in vitro might be predominantly attributable to individual
genetic backgrounds (Chen et al., 2016; Lek et al., 2016).
GATA4 is an obvious choice for a genetic modifier, given
its expression in the DE, genetic interaction with Gata6
in mice, and the identification of rare GATA4 heterozygous
patients with pancreatic agenesis, as well as our finding
that GATA4 is bound and regulated by GATA6 in vitro (Fig-
ure 3) (D’Amato et al., 2010; Freyer et al., 2015; Morriseyet al., 1996; Shaw-Smith et al., 2014). Indeed, Shi et al.
(2017) elegantly show dosage-dependent effects of GATA4
alleles on phenotypes associated with GATA6 heterozygos-
ity during in vitro differentiation. Despite reports of consid-
erable phenotypic variation between family members with
the same GATA6 mutation (Bonnefond et al., 2012; De
Franco et al., 2013; Yau et al., 2017), in some cases a parent
is a mosaic for the phenotype, so the variation between
parental and offspring phenotypes can be explained by
different mutation load in target tissues (Yau et al., 2017).
If the variation in the human phenotype altered signifi-
cantly with the genetic background, then most cases with
severe pancreatic agenesis would likely be born to parents
with the same mutation, but a 50% different (protective)
genetic background would have a milder phenotype. How-
ever, this is not the case, as the vast majority of severe
pancreatic agenesis is from de novo mutations (De Franco
et al., 2013; Lango Allen et al., 2011). This means it is
possible, but not likely, that genetic background explains
why Shi et al. (2017) engineered, using CRISPR/Cas9,
the common GATA6 agenesis mutation c.1366C>T
(p.Arg456Cys) in HUES8 cells—the same allele present in
our patient A-derived iPSC line (GATA6R456C/+)—and
observed no heterozygous phenotype at the DE or pancre-
atic progenitor (PDX1+) stages, whereas we do, at both the
DE stage and beyond.
In addition to line-to-line differentiation efficiencies
in vitro (Cahan and Daley, 2013; Ortmann and Vallier,
2017), fundamental differences in the differentiation pro-
tocols themselvesmayunderlie (or contribute to) the results
we report here and those published by Shi et al. (2017) and
Tiyaboonchai et al. (2017). For example, the growth
factor and small-molecule components as well as medium
formulations differ substantially for the first 3 days of DE
differentiation among the three studies. Furthermore, our
differentiation protocol relies on culture media devoid of
serum or complex extracellular matrices such as Matrigel.
Thus, the minimalist approach of our system could exacer-
bate the GATA6 phenotype, revealing a function for this
gene that is otherwise masked. This possibility highlights
the importance of culture conditions to study gene
function in hPSCs and during their differentiation. Tiya-
boonchai et al. (2017) additionally show that a GATA6
heterozygous iPSC linederived fromanagenesis patient un-
expectedly produced b-like cells in vitro. Simply reducing
the concentration of retinoic acid 80-fold led to statistically
significantly fewer PDX1+ cells compared with a wild-type
iPSC line that showed negligible sensitivity to the same cul-
ture regime. Indeed, current hPSC pancreatic differentia-
tion protocols have been highly tailored and refined,
providing redundant and reinforcing signals that perhaps
reconfigure underlying GRNs and bypass certain in vivo ge-
netic requirements. Moreover, it must be acknowledgedStem Cell Reports j Vol. 12 j 57–70 j January 8, 2019 67
that adherent differentiation fails to achieve the 3D
complexity of human endoderm formation in vivo. Thus,
studies of early pancreatic lineage commitment would
greatly benefit from universal protocols standardized intra-
and inter-laboratory in an effort to minimize line-to-line
and protocol-to-protocol differences.EXPERIMENTAL PROCEDURES
Human Pluripotent Stem Cell Culture and Pancreatic
Differentiation
hESCs (H9 [WA09 from www.wicell.org]), hiPSCs (FSPS13.B
derived in-house from human fibroblasts [http://www.hipsci.org/
lines/#/lines/HPSI0813i-fpdm_2]), and GATA6 patient-derived
iPSCs, from patients A and B, were routinely cultured under
feeder-free conditions on vitronectin-coated (STEMCELL Technol-
ogies #07180) tissue culture plates (Corning) with Essential 8 Me-
dium (Life Technologies #A1517001). All tissue culture was carried
out in 5%CO2 at 37
C. Pancreatic differentiationwas carried out as
previously described (Cho et al., 2012), with modifications
described in Supplemental Experimental Procedures.GATA6 Patient Samples
The generation of GATA6 patient-derived hiPSCs was approved
by the Great Ormond Street Hospital and Institute of Child
Health Research Ethics Committee (ethics reference: 08/
H0713/82), and informed consent was obtained from all pa-
tients. Skin punch biopsy samples were collected from patients
and all hiPSC lines used were derived and validated by the Cam-
bridge Biomedical Research Center hiPSC Core Facility. Reprog-
ramming of the GATA6 patient fibroblasts to derive GATA6
patient iPSCs was done by the hiPSC core facility at the Anne
McLaren Laboratory for Regenerative Medicine using Sendai
virus reprogramming.GATA6-Mutant and GATA6-emGFP Reporter hPSC
Derivation
The construction of TALEN vectors, their introduction into H9 or
13.B cells via electroporation, and the screening of drug-resistant
clones are described in detail in the Supplemental Experimental
Procedures. Two TALEN pairs were generated, each targeting a
different site within GATA6 exon 2. The first TALEN pair targets a
site that is 6 bp downstreamof the firstGATA6 start codon. The sec-
ond targets a site that is 149 bp downstream of the second GATA6
start codon. Primers used for TALEN construction and screening of
genomic DNA are listed in Table S2.RNA- and ChIP-Sequencing Analysis of Gene
Expression
Library preparation and deep sequencing were performed at the
Wellcome Trust Sanger Institute (Hinxton, UK). RNA-seq and
ChIP-seq were run on Illumina Hiseq v.3 and v.4, respectively,
with read length 75 bp and paired ends, and a library fragment
size of 100–1,000 bp using a multiplex strategy. RNA-seq and
ChIP-seq samples were run in biological triplicates and duplicates,68 Stem Cell Reports j Vol. 12 j 57–70 j January 8, 2019respectively. Additional details of howRNA-seq andChIP-seq reads
were aligned and analyzed can be found in the Supplemental
Experimental Procedures.
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